Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Commenting is limited to medical professionals. To comment please Log-in.
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Close
Contributor Information
Authors
John Anello
Editorial Director, Medscape Drugs & Diseases
Brian Feinberg
Senior Editor, Medscape Drugs & Diseases
John Heinegg
Senior Editor, Medscape Drugs & Diseases
Richard Lindsey
Senior Editor, Medscape Drugs & Diseases
Boggs W. New Guidelines Support Expanded Use of TAVR. Reuters Health Information. March 24, 2017.
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Mar 10. http://circ.ahajournals.org/content/early/2017/03/14/CIR.0000000000000503
Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. Published online before print March 6, 2017. http://ascopubs.org/doi/full/10.1200/JCO.2016.70.7257
Arber DA, Borowitz MJ, Cessna M, et al. Initial Diagnostic Workup of Acute Leukemia: Guideline from the College of American Pathologists and the American Society of Hematology. Arch Pathol Lab Med. 2017 Feb 22. http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2016-0504-CP
Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology [published online ahead of print February 6, 2017]. Am J Clin Pathol. 2017 Feb 3. https://academic.oup.com/ajcp/article-lookup/doi/10.1093/ajcp/aqw209
Harrison P. ASCO issues guideline on castrate-resistant prostate cancer. Medscape News & Perspective. Oncology. WebMD Inc. April 25, 2017.http://www.medscape.com/viewarticle/878998
Virgo KS, Basch E, Loblaw DA, et al. Second-Line Hormonal Therapy for Men With Chemotherapy-Naive, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. J Oncol Pract. 2017 Apr 26. http://ascopubs.org/doi/full/10.1200/JCO.2017.72.8030
Nelson R. ASCO guideline for sexual/gender minority cancer patients. Medscape News & Perspective. Oncology. WebMD Inc. April 4, 2017. http://www.medscape.com/viewarticle/878151
Griggs J, Maingi S, Blinder V, et al. American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations. J Clin Oncol. 2017 Apr 3. http://ascopubs.org/doi/full/10.1200/JCO.2016.72.0441
Harrison P. ASTRO Releases First Guidelines for Oropharyngeal Cancer. Medscape News & Perspective. WebMD Inc. April 20, 2017. http://www.medscape.com/viewarticle/878890
Sher DJ, Adelstein DJ, Bajaj GK, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2017 Apr 11. http://www.practicalradonc.org/article/S1879-8500(17)30045-0/fulltext
Close
Image Zoom
Close
Feedback
Please do not use this form to submit personal or patient medical information or to report adverse drug events. You are encouraged to report adverse drug event information to the FDA.
Comments